|Place of Origin:||China|
|Model Number:||18 mcg/capsule|
|Minimum Order Quantity:||10000 boxes|
|Payment Terms:||L/C, T/T|
|Supply Ability:||100, 000 boxes per day|
|Product:||Tiotropium Bromide Inhalation Powder||Specification:||18 Mcg/capsule|
18 mcg/capsule Aerosol Medication Tiotropium Bromide Powder For Inhalation
Product : Tiotropium Bromide Inhalation Powder
Specification : 18 mcg/capsule
Standard : BP, USP
Packing : 30capsules/blister/box
Tiotropium bromide inhalation powder consists of a capsule dosage form containing a dry powder formulation of tiotropium intended for oral inhalation only with the HandiHaler device.
Each capsule contains 18 mcg tiotropium (equivalent to 22.5 mcg tiotropium bromide monohydrate) blended with lactose monohydrate as the carrier.
The dry powder formulation within the capsule is intended for oral inhalation only.
Indications and Usage :
Tiotropium bromide inhalation powder is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Tiotropium is a long–acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3–receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies prevention of methacholine–induced bronchoconstriction effects were dose–dependent and lasted longer than 24 hours. The bronchodilation following inhalation of tiotropium is predominantly a site–specific effect.
Mechanism of action
Tiotropium is a muscarinic receptor antagonist, often referred to as an antimuscarinic or anticholinergic agent. Although it does not display selectivity for specific muscarinic receptors, on topical application it acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation, thus producing a bronchodilatory effect.